-transparent.png){kind=logo}
The pharmacokinetics of cefroxadine, a new orally active broad-spectrum cephalosporin, was studied in healthy volunteers and patients with impaired renal function after a single oral dose of 500 mg. The pharmacokinetic parameters of cefroxadine were obtained by analysing the serum level data of the drug based on a one-compartment open model. The mean serum half-life of cefroxadine was 0.97 h in healthy subjects, and was prolonged to 41.7 h in patients with a creatinine clearance of less than 5 ml/min. There was a significant linear correlation (p less than 0.001) between the elimination rate constant of the drug and the creatinine clearance. In healthy subjects, 71% of the administered dose was excreted in the urine collected over the first 6 h.
M Ohkawa, and
K Takamae, and
M Shimamura, and
K Kuroda, and
S Awazu
December 1980,
The Japanese journal of antibiotics,
M Ohkawa, and
K Takamae, and
M Shimamura, and
K Kuroda, and
S Awazu
November 1997,
Arzneimittel-Forschung,
M Ohkawa, and
K Takamae, and
M Shimamura, and
K Kuroda, and
S Awazu
July 1989,
Journal of chemotherapy (Florence, Italy),
M Ohkawa, and
K Takamae, and
M Shimamura, and
K Kuroda, and
S Awazu
October 1990,
International journal of clinical pharmacology, therapy, and toxicology,
M Ohkawa, and
K Takamae, and
M Shimamura, and
K Kuroda, and
S Awazu
November 1986,
The Journal of antimicrobial chemotherapy,
M Ohkawa, and
K Takamae, and
M Shimamura, and
K Kuroda, and
S Awazu
December 1981,
The Journal of antimicrobial chemotherapy,
M Ohkawa, and
K Takamae, and
M Shimamura, and
K Kuroda, and
S Awazu
April 1990,
Antimicrobial agents and chemotherapy,
M Ohkawa, and
K Takamae, and
M Shimamura, and
K Kuroda, and
S Awazu
February 1994,
The Journal of antimicrobial chemotherapy,
M Ohkawa, and
K Takamae, and
M Shimamura, and
K Kuroda, and
S Awazu
January 1980,
Chemotherapy,
M Ohkawa, and
K Takamae, and
M Shimamura, and
K Kuroda, and
S Awazu
January 1987,
Drugs,
